title: Characteristics and outcomes of anterior hyaloidal fibrovascular proliferation in lasered retinopathy of prematurity. The Indian Twin Cities Retinopathy of Prematurity Study (ITCROPS) report number 4.
abstract: To describe the characteristics and treatment outcomes of an unreported, late vitreous hemorrhage due to anterior hyaloidal fibrovascular proliferation in laser-regressed retinopathy of prematurity (ROP). Interventional case series. In the ongoing Indian Twin Cities ROP study database, consecutive cases with isolated late vitreous hemorrhage at least one year after laser-regressed disease were analyzed retrospectively. Anterior hyaloidal fibrovascular proliferation was diagnosed primarily using scleral depression. Anterior retinal cryopexy with adjunctive treatments was performed. The main outcome measure was clinical resolution of new vessels with no recurrent hemorrhage over a 1-year period. Vitreous hemorrhage, at two to eight years of age, developed in three eyes of three children out of 1,168 ROP lasered eyes. All had received laser for zone I disease as neonates, with no subsequent sequelae. Evaluation revealed filiform new vessels at the posterior vitreous base involving inferior 180° with absence of any other source of hemorrhage. All underwent anterior retinal cryopexy to the affected area. Simultaneous additional treatment, based on intraoperative findings, included one case each of peripheral laser photocoagulation, lens-sparing vitrectomy and intravitreal bevacizumab. All three showed successful regression and non-recurrence of vitreous hemorrhage with improvement of vision >20/40 at an intermediate follow-up of two years. Anterior hyaloidal fibrovascular proliferation is an unreported and rare cause of vitreous hemorrhage, appearing years after laser-regressed ROP. It has a good response to interventional treatment. Meticulous scleral depression of the vitreous base under anesthesia is useful to detect this rare source of vitreous hemorrhage.
authors.affiliation: Srimati Kanuri Santhamma Centre for Vitreoretinal Diseases, LV Prasad Eye Institute, Kallam Anji Reddy Campus, LV Prasad Marg, Banjara Hills, Hyderabad, 500034, India.
authors.forename: Vivek Pravin
authors.initials: VP
authors.lastname: Dave
authors.forename: Subhadra
authors.initials: S
authors.lastname: Jalali
authors.forename: Padmaja Kumari
authors.initials: PK
authors.lastname: Rani
authors.forename: Tapas Ranjan
authors.initials: TR
authors.lastname: Padhi
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D000068258:Bevacizumab; D002648:Child; D002675:Child, Preschool; D003452:Cryosurgery / Q000379:methods; D005128:Eye Diseases / Q000150:complications* / Q000209:etiology; D005355:Fibrosis; D006801:Humans; D007194:India; D017075:Laser Coagulation / Q000009:adverse effects*; D009389:Neovascularization, Pathologic / Q000150:complications / Q000209:etiology; D011183:Postoperative Complications / Q000628:therapy; D012178:Retinopathy of Prematurity / Q000601:surgery*; D012189:Retrospective Studies; D014792:Visual Acuity; D014823:Vitreous Hemorrhage / Q000209:etiology / Q000628:therapy
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab
references.citation: Am J Ophthalmol. 2011 Apr;151(4):719-724.e2
references.pmid: 21257156
references.citation: Am J Ophthalmol. 2010 Jul;150(1):10-15.e1
references.pmid: 20609704
references.citation: J AAPOS. 2008 Apr;12(2):181-5
references.pmid: 18083589
references.citation: Br J Ophthalmol. 2003 Mar;87(3):365-6
references.pmid: 12598460
references.citation: Am J Ophthalmol. 1993 Mar 15;115(3):321-6
references.pmid: 7680186
references.citation: Am J Ophthalmol. 1987 Dec 15;104(6):607-13
references.pmid: 2446501
references.citation: Indian J Ophthalmol. 2003 Mar;51(1):89-99
references.pmid: 12701873
references.citation: Arch Ophthalmol. 2010 Jun;128(6):663-71
references.pmid: 20385926
references.citation: Arch Ophthalmol. 2003 Dec;121(12):1684-94
references.pmid: 14662586
references.citation: Trans Am Ophthalmol Soc. 2004;102:233-48; discussion 248-50
references.pmid: 15747762
references.citation: Am J Ophthalmol. 2003 Aug;136(2):258-63
references.pmid: 12888047
references.citation: Am J Ophthalmol. 1998 Jul;126(1):82-90
references.pmid: 9683153
references.citation: Ophthalmology. 1990 Jun;97(6):821-6
references.pmid: 2374688
references.citation: Ophthalmology. 2000 Sep;107(9):1729-36
references.pmid: 10964837
references.citation: Ophthalmology. 2006 May;113(5):848-52
references.pmid: 16650682
references.citation: Br J Ophthalmol. 2004 Feb;88(2):243-6
references.pmid: 14736784
references.citation: Am J Ophthalmol. 1987 Dec 15;104(6):614-8
references.pmid: 2446502
references.citation: Am J Ophthalmol. 2006 May;141(5):966-8
references.pmid: 16678524
references.citation: Ophthalmology. 1996 Feb;103(2):315-22
references.pmid: 8594520